Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dave Clennell joins DxS

This article was originally published in Clinica

Executive Summary

Molecular diagnostics company DxS has appointed Dave Clennell director of quality. Mr Clennell has worked in the healthcare industry for 30 years, and was previously director of quality for Lombard Medical Technologies. He has also been employed by Johnson & Johnson, Genzyme and SmithKline Beecham Pharmaceuticals. Manchester, UK-based DxS plans to submit its TheraScreen K-RAS mutation kit to the US FDA "imminently" – it CE marked the test for sale in Europe in January 2008. The diagnostic detects mutations in the KRAS gene that are linked with decreased efficacy of EGFR inhibitors like Amgen's Vectibix (panitumumab), which are used to treat colorectal cancer.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel